If you have patients who would benefit from specialized obesity medicine support, you are welcome to refer them.
And if you think someone you know might be interested in this edition of Market Shake, feel free to simply forward this email or click the button below
Jungnik A, Arrubla Martinez J, Plum-Mrschel L, Kapitza C, Lamers D, Thamer C, et al
With triple agonist retatrutide, we set out to make a molecule that could help patients achieve substantial A1C reduction and weight loss
Instead of targeting two hormone pathways, Retatrutide activates three: GLP-1 GIP Glucagon receptors Because it targets an additional metabolic pathway, researchers are studying whether Retatrutide may influence both appetite regulation and energy expenditure
Most people notice results within 12-24 hours